1. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

    JAMA 313(12):1249 (2015) PMID 25742465

    Safe and effective vaccines and drugs are needed for the prevention and treatment of Ebola virus disease, including following a potentially high-risk exposure such as a needlestick. To assess response to postexposure vaccination in a health care worker who was exposed to the Ebola virus. Case re...
  2. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

    Journal of Clinical Oncology 33(1):74 (2015) PMID 25403209 PMCID PMC4268254

    Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant human...
  3. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

    Journal of Clinical Oncology 33(1):74 (2015) PMID 25403209 PMCID PMC4268254

    Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant human...
  4. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

    JAMA 313(12):1249 (2015) PMID 25742465

    Safe and effective vaccines and drugs are needed for the prevention and treatment of Ebola virus disease, including following a potentially high-risk exposure such as a needlestick. To assess response to postexposure vaccination in a health care worker who was exposed to the Ebola virus. Case re...
  5. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.

    JAMA 313(12):1249 (2015) PMID 25742465

    Safe and effective vaccines and drugs are needed for the prevention and treatment of Ebola virus disease, including following a potentially high-risk exposure such as a needlestick. To assess response to postexposure vaccination in a health care worker who was exposed to the Ebola virus. Case re...
  6. Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus.

    AIDS 28(8):1091 (2014) PMID 24492253

    Determining the precise lifespan of human T-cell is challenging due to the inability of standard techniques to distinguish between dividing and dying cells. Here, we measured the lifespan of a pool of T cells that were derived from a single cell 'naturally' labelled with a single integrated clon...
  7. Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus.

    AIDS 28(8):1091 (2014) PMID 24492253

    Determining the precise lifespan of human T-cell is challenging due to the inability of standard techniques to distinguish between dividing and dying cells. Here, we measured the lifespan of a pool of T cells that were derived from a single cell 'naturally' labelled with a single integrated clon...
  8. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

    Journal of Antimicrobial Chemotherapy 69(4):1104 (2014) PMID 24275116 PMCID PMC3956369

    The optimal individualized selection of antiretroviral drugs in resource-limited settings is challenging because of the limited availability of drugs and genotyping. Here we describe the development of the latest computational models to predict the response to combination antiretroviral therapy ...
  9. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

    Journal of Antimicrobial Chemotherapy 69(4):1104 (2014) PMID 24275116 PMCID PMC3956369

    The optimal individualized selection of antiretroviral drugs in resource-limited settings is challenging because of the limited availability of drugs and genotyping. Here we describe the development of the latest computational models to predict the response to combination antiretroviral therapy ...
  10. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

    Journal of Antimicrobial Chemotherapy 69(4):1104 (2014) PMID 24275116 PMCID PMC3956369

    The optimal individualized selection of antiretroviral drugs in resource-limited settings is challenging because of the limited availability of drugs and genotyping. Here we describe the development of the latest computational models to predict the response to combination antiretroviral therapy ...
  11. Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis.

    PLoS Pathogens 10(3):e1003976 (2014) PMID 24603698 PMCID PMC3946368

    HIV infection and the associated chronic immune activation alter T cell homeostasis leading to CD4 T cell depletion and CD8 T cell expansion. The mechanisms behind these outcomes are not totally defined and only partially explained by the direct cytopathic effect of the virus. In this manuscript...
  12. Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection.

    PLoS ONE 9(6):e98989 (2014) PMID 24896094 PMCID PMC4045808

    IL-27 is an immunomodulatory cytokine with potent anti-HIV properties in PBMCs, CD4+ T cells, macrophages and immature dendritic cells. Previous smaller studies have suggested that HIV-1 infection may alter IL-27 and influence HIV-1 pathogenesis. The aim of this study was to examine the relation...
  13. Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.

    PLoS ONE 9(7):e101785 (2014) PMID 25004134 PMCID PMC4086938

    Data from prospectively planned cohort studies on risk of major clinical outcomes and prognostic factors for patients with influenza A(H1N1)pdm09 virus are limited. In 2009, in order to assess outcomes and evaluate risk factors for progression of illness, two cohort studies were initiated: FLU 0...
  14. Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.

    PLoS ONE 9(7):e101785 (2014) PMID 25004134 PMCID PMC4086938

    Data from prospectively planned cohort studies on risk of major clinical outcomes and prognostic factors for patients with influenza A(H1N1)pdm09 virus are limited. In 2009, in order to assess outcomes and evaluate risk factors for progression of illness, two cohort studies were initiated: FLU 0...
  15. Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.

    PLoS ONE 9(7):e101785 (2014) PMID 25004134 PMCID PMC4086938

    Data from prospectively planned cohort studies on risk of major clinical outcomes and prognostic factors for patients with influenza A(H1N1)pdm09 virus are limited. In 2009, in order to assess outcomes and evaluate risk factors for progression of illness, two cohort studies were initiated: FLU 0...
  16. siRNA enhances DNA-mediated interferon lambda-1 response through crosstalk between RIG-I and IFI16 signalling pathway.

    Nucleic Acids Research 42(1):583 (2014) PMID 24049081 PMCID PMC3874163

    In addition to silencing specific genes, small interfering RNA (siRNA) transfection is also associated with the non-specific induction of inflammatory cytokines and type I interferon. Those so-called "off-target" effects have considerable implications for the interpretation of in vitro studies a...
  17. A model of federal interagency cooperation: the National Interagency Confederation for Biological Research.

    Biosecurity and Bioterrorism 12(3):144 (2014) PMID 24819736 PMCID PMC4043433

    The terrorist attacks of September 11 and the anthrax mailings a month later prompted a sweeping response by the federal government to improve the preparedness of the US to meet the potential threat posed by a terrorist using a biological agent. This response transcended traditional interagency ...
  18. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

    Cytokine & Growth Factor Reviews 24(6):571 (2013) PMID 23962745 PMCID PMC3851681

    Interleukin 27 (IL-27) is an immunomodulatory cytokine with important roles in both the innate and adaptive immune systems. In the last five years, the addition of exogenous IL-27 to primary cell cultures has been demonstrated to decrease HIV-1 replication in a number of cell types including per...
  19. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

    Cytokine & Growth Factor Reviews 24(6):571 (2013) PMID 23962745 PMCID PMC3851681

    Interleukin 27 (IL-27) is an immunomodulatory cytokine with important roles in both the innate and adaptive immune systems. In the last five years, the addition of exogenous IL-27 to primary cell cultures has been demonstrated to decrease HIV-1 replication in a number of cell types including per...
  20. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.

    Cytokine & Growth Factor Reviews 24(6):571 (2013) PMID 23962745 PMCID PMC3851681

    Interleukin 27 (IL-27) is an immunomodulatory cytokine with important roles in both the innate and adaptive immune systems. In the last five years, the addition of exogenous IL-27 to primary cell cultures has been demonstrated to decrease HIV-1 replication in a number of cell types including per...